

Inventors: Mazar and Jones  
Docket No.: 66782-056  
Filed: Herewith  
Page 3

**CURRENT STATUS OF ALL CLAIMS**

Claims 1-14 (canceled)

15. (New) A non-naturally occurring peptide, comprising the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu (SEQ ID NO: 2), wherein said peptide has one or more of the following activities:

(a) at least about 20% of the biological activity of Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-Am in one or more of the following *in vitro* bioassays: (i) invasion in a Matrigel assay; (ii) endothelial tube formation on Matrigel, or (iii) endothelial tube formation on a fibrin matrix in the presence of basic fibroblast growth factor and vascular endothelial growth factor; or

(b) competes with labeled Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-Am for binding to a cell or molecule which has a binding site for Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-Am.

16. (New) The peptide of claim 15, wherein said peptide is labeled.

17. (New) The peptide of claim 16, wherein said label is selected from a radioactive, fluorogenic, chromogenic, or other chemical label.

18. (New) The peptide of claim 15, wherein said peptide is conjugated to a therapeutic agent.

Inventors: Mazar and Jones  
Docket No.: 66782-056  
Filed: Herewith  
Page 4

19. (New) The peptide of claim 15, wherein said peptide is acetylated at the amino terminus and amidated at the carboxy terminus.

20. (New) A pharmaceutical composition, comprising the peptide of claim 15.

21. (New) A peptide comprising the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu (SEQ ID NO: 2), wherein said peptide has 8 amino acid residues.

22. (New) The peptide of claim 21, wherein said peptide is labeled.

23. (New) The peptide of claim 22, wherein said label is selected from a radioactive, fluorogenic, chromogenic, or other chemical label.

24. (New) The peptide of claim 21, wherein said peptide is conjugated to a therapeutic agent.

25. (New) The peptide of claim 21, wherein said peptide is acetylated at the amino terminus and amidated at the carboxy terminus.

26. (New) A pharmaceutical composition, comprising the peptide of claim 21.

Inventors: Mazar and Jones  
Docket No.: 66782-056  
Filed: Herewith  
Page 5

27. (New) A peptide consisting of the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu (SEQ ID NO: 2).

28. (New) The peptide of claim 27, wherein said peptide is labeled.

29. (New) The peptide of claim 28, wherein said label is selected from a radioactive, fluorogenic, chromogenic, or other chemical label.

30. (New) The peptide of claim 27, wherein said peptide is conjugated to a therapeutic agent.

31. (New) The peptide of claim 27, wherein said peptide is acetylated at the amino terminus and amidated at the carboxy terminus.

32. (New) A pharmaceutical composition, comprising the peptide of claim 27.